Prostate News and Research

RSS

Recent study shows drinking coffee protects against head and neck cancer

Data on the effects of coffee on cancer risk have been mixed. However, results of a recent study add to the brewing evidence that drinking coffee protects against cancer, this time against head and neck cancer.

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospital Centre) in Pointe - Pitre (urology department, University of the French West Indies and Guiana) and from the Center for Analytical Research and Technology (University of Li-ge, Belgique), show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer.

23 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

EIN News expands health news-monitoring coverage

With impending lawsuits from states, an uprising from the Tea Party sect and an outpouring of rhetoric from both major parties, the healthcare debate is far from over.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

Protect Your Lungs, LUNGevity Foundation announce merger

To combat the nation's number one cancer killer, non-profit organizations Protect Your Lungs and LUNGevity Foundation today announced they will join forces in an effort to fund research and hope for a cure for lung cancer. Together, the new organization hopes to create the same successful improvements for lung cancer mortality rates as those experienced by breast, prostate, and colon cancer. The merged organization, committed to elevating lung cancer on the national agenda, will operate under the name LUNGevity Foundation with offices in Washington, D.C. and Chicago.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

$FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer$

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.

18 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

The American Society for Radiation Oncology (ASTRO) commends the Medicare Payment Advisory Commission (MedPAC) for highlighting concerns about physician self-referral in cancer care in its report released yesterday. We urge the commission to make recommendations to Congress to end abuses of the physician self-referral law in radiation oncology enabled by the "in-office ancillary services exception."

17 Jun 2010

LCA commends Senator John Kerry for backing Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance commended Senator John Kerry (D-MA) for backing the Lung Cancer Mortality Reduction Act, S.332. This is the first ever authorizing legislation that establishes a multi-agency, comprehensive program targeted at lung cancer.

17 Jun 2010

Prevention, awareness of enlarged prostate can help save lives

We live in a country of excess where size often matters most. Supersize, grande, max, king size - but is bigger always better? Certainly not when it comes to male health and an enlarged prostate.

16 Jun 2010

Diabetes associated with increased risk of cancer

A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis.

16 Jun 2010

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths -- in some cases, even how aggressively to test -- along with a push for more of the informed-choice programs.

16 Jun 2010

Prostate News and Research

Recent study shows drinking coffee protects against head and neck cancer

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

EIN News expands health news-monitoring coverage

Exelixis announces regaining of rights to develop and commercialize XL184

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Active surveillance sufficient for patients with low-risk prostate cancer

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

Protect Your Lungs, LUNGevity Foundation announce merger

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

CINJ researchers combine series of vaccination injections to treat prostate cancer

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

LCA commends Senator John Kerry for backing Lung Cancer Mortality Reduction Act

Prevention, awareness of enlarged prostate can help save lives

Diabetes associated with increased risk of cancer

Cancer overtreatment raises concern; Physicians tend to use new technology even before solid evidence backs it

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News